SCHEMBL3763545

SCHEMBL3763545

CC1(C)CC(=O)c2sc(N3CCOCC3)c(-c3cccc(NC(=O)C(=O)N4CCOCC4)c3)c2C1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PRKDC P78527 2/20 0.41
NPC1 O15118 8/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
PIK3CA P42336 2/20 0.36
PIK3R1 P27986 1/20 0.36
CHRNA7 P36544 1/20 0.36
BRD4 O60885 3/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760075 0.91 PRKDC (0.42) RAB9APRKDCNPC1PIK3CAPIK3R1
SCHEMBL3763361 0.91 PRKDC (0.42) RAB9APRKDCNPC1PIK3CAPIK3R1
SCHEMBL3751898 0.91 NPC1 (0.46) RAB9ASMN1; SMN2PRKDCNPC1KDM4E
SCHEMBL3766528 0.90 PRKDC (0.52) RAB9AHTTPRKDCNPC1KDM4E
SCHEMBL16161718 0.88 PRKDC (0.40) RAB9ASMN1; SMN2PRKDCNPC1ALDH1A1
SCHEMBL3765924 0.88 PIK3CA (0.44) RAB9AHTTPRKDCNPC1MEN1
SCHEMBL3759355 0.87 PRKDC (0.41) RAB9ASMN1; SMN2PRKDCNPC1ALDH1A1
SCHEMBL3757637 0.87 KDM4E (0.48) RAB9AHTTSMN1; SMN2PRKDCNPC1
SCHEMBL16161666 0.87 POLB (0.42) RAB9AHTTSMN1; SMN2PRKDCNPC1
SCHEMBL3759849 0.86 PRKDC (0.37) PRKDCMAPTKMT2APIK3CABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA RAB9A 713/4885HTT 1234/4885SMN1; SMN2 1864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.